Adam Grossman

Adam S. Grossman, President & Chief Executive Officer at ADMA Biologics, will assume the additional role of Interim Chief Financial Officer, effective April 1, 2024. Mr. Grossman has been the driving force behind ADMA Biologics’ mission to develop and bring to market novel plasma-derived products to address certain unmet medical needs for immune c... ompromised patients. He began his career as a hospital-based plasma products sales representative focusing on immune compromised patients. This opportunity provided him with a first-hand view of certain challenges patients faced while gaining an understanding of how some patients' medical needs are handled by treating clinicians. Mr. Grossman has over 25 years of experience in the blood and plasma products industry which includes experience in launching new products, building and managing national and international sales forces as well as managing and designing clinical trials. Additionally, he has negotiated and completed numerous business development transactions. Under his leadership, Mr. Grossman brought ADMA public in 2013 and has completed over $300M in capital markets financing and debt transactions throughout his career. Mr. Grossman led the asset acquisition of the Biotest Therapy Business Unit in 2017, which transformed ADMA Biologics into one of a handful of vertically integrated plasma products manufacturing companies based in the US. Subsequent to the asset acquisition, he is credited with leading the successful integration of business operations, revamping and overhauling the site-wide quality and compliance functions, and leading the regulatory affairs strategy resulting in FDA approvals for BIVIGAM®’s Prior Approval Supplement (PAS) and ASCENIV™’s Biologics License Application (BLA), as well as the receipt of a new FDA license for the Boca Raton manufacturing plant. Mr. Grossman has been a member of the ADMA Biologics Board of Directors since 2007, has served as the Company’s President and Chief Executive Officer since October 2011, as the Company’s Interim Chief Financial Officer since April 2024 and as the Company’s President and Chief Operating Officer between 2007 and October 2011. In 2016, he was issued several patents, which are the basis for the manufacturing methods and composition for ASCENIV™. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, positions he held between 1994 and 2011. Previously, he worked at MedImmune, Inc. as part of the marketing team for respiratory syncytial virus and cytomegalovirus immunoglobulins and at the American Red Cross, where he participated in the launch of new products with the Biomedical Services division. Mr. Grossman currently serves as the Chair of the North America Board of Directors of the Plasma Protein Therapeutics Association, since September 2023. Mr. Grossman is a graduate of American University, receiving a BS in Business Administration, with a specialization in International Business and Marketing.Read More